Avraham Pharmaceuticals' Series E Round

Avraham Pharmaceuticals raised a round of funding on February 25, 2016.

Avraham Pharmaceuticals is a pharmaceutical company developing products for treatment and/or prevention of neurodegenerative disorders. The company's lead product candidate, ladostigil, is in Phase 2 …

Articles about Avraham Pharmaceuticals' Series E Round: